Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioNTech: 'We Could Produce New COVID Variant Vaccine In Six Weeks'

Vaccine Developer Is Confident Existing Vaccine Still Works

Executive Summary

The speed of the new messenger RNA platforms could once again come to the rescue, but the expectation is that existing vaccines should remain effective against the emerging strain.

You may also be interested in...



US COVID-19 Vaccination Rollout On Track After Early Bumps, J.P. Morgan Panelists Say

US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.

Pfizer/BioNTech COVID-19 Vaccine Wins EU Green Light

The first COVID-19 vaccine will shortly be available to the EU member states. The European Medicines Agency says that uncertainties remain over the ability of the vaccine to prevent transmission of the coronavirus and whether the new variant strain will render this and other vaccines less effective.

Pfizer/BioNTech COVID-19 Vaccine Wins EU Approval

The first COVID-19 vaccine will shortly be available to the EU member states, after the European Commission today approved Pfizer/BioNTech's BNT162b2 just hours after the European Medicines Agency issued a positive opinion on the product. The EMA says that uncertainties remain over the ability of the vaccine to prevent transmission of the coronavirus and whether the new variant strain will render this and other vaccines less effective. 

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS143519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel